InterCure Ltd. (NASDAQ:INCR – Get Rating) saw a significant decrease in short interest in June. As of June 15th, there was short interest totalling 101,200 shares, a decrease of 26.7% from the May 31st total of 138,000 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily trading volume, of 59,900 shares, the days-to-cover ratio is currently 1.7 days.
Several institutional investors and hedge funds have recently modified their holdings of INCR. Citigroup Inc. increased its holdings in shares of InterCure by 9,567.9% in the 1st quarter. Citigroup Inc. now owns 5,124 shares of the company’s stock valued at $36,000 after purchasing an additional 5,071 shares during the period. Davy Global Fund Management Ltd acquired a new position in shares of InterCure in the 1st quarter valued at about $152,000. Goldman Sachs Group Inc. acquired a new position in shares of InterCure in the 3rd quarter valued at about $283,000. ETF Managers Group LLC acquired a new position in shares of InterCure in the 4th quarter valued at about $3,592,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of InterCure in the 4th quarter valued at about $5,423,000. Institutional investors own 9.34% of the company’s stock.
INCR stock traded up $0.07 during mid-day trading on Friday, reaching $5.86. 1,341 shares of the stock traded hands, compared to its average volume of 33,830. The company has a current ratio of 1.67, a quick ratio of 1.26 and a debt-to-equity ratio of 0.07. InterCure has a 52-week low of $4.50 and a 52-week high of $8.77. The company has a market cap of $250.46 million and a P/E ratio of 48.83. The stock’s fifty day moving average is $6.26 and its 200-day moving average is $6.51.
InterCure (NASDAQ:INCR – Get Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported $0.11 EPS for the quarter. InterCure had a net margin of 5.38% and a return on equity of 3.23%. The company had revenue of $27.29 million during the quarter.
About InterCure (Get Rating)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector.